Page last updated: 2024-11-05

tetraethylammonium and Hypercholesterolemia

tetraethylammonium has been researched along with Hypercholesterolemia in 4 studies

Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)

Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.

Research Excerpts

Excerpt	Relevance	Reference
" Third, bradykinin, but not acetylcholine, stimulates K(+)(Ca) channel-mediated vasodilation in healthy subjects, whereas in hypercholesterolemia, K(+)(Ca) channel-mediated vasodilation compensates for the reduced nitric oxide activity."	5.15	Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. ( Kavtaradze, N; Lin, J; Manatunga, A; Murrow, JR; Ozkor, MA; Quyyumi, AA; Rahman, AM, 2011)
"In vivo, hypercholesterolemia is associated with an altered balance between NO-mediated and NO-independent K(Ca) channel contributions to resting vasomotor tone and impairment of both mechanisms of endothelium-dependent vasodilatation."	1.31	Effect of hypercholesterolemia on Ca(2+)-dependent K(+) channel-mediated vasodilatation in vivo. ( Jeremy, RW; McCarron, H, 2000)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Heaps, CL	1
Jeffery, EC	1
Laine, GA	1
Price, EM	1
Bowles, DK	1
Ozkor, MA	1
Murrow, JR	1
Rahman, AM	1
Kavtaradze, N	1
Lin, J	1
Manatunga, A	1
Quyyumi, AA	1
Moroe, H	1
Fujii, H	1
Honda, H	1
Arai, K	1
Kanazawa, M	1
Notoya, Y	1
Kogo, H	1
Jeremy, RW	1
McCarron, H	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Physiology and Pathologic Role of Endothelium-Derived Hyperpolarizing Factor in Humans[NCT00166166]			Phase 2	174 participants (Actual)	Interventional	2002-07-31	Terminated (stopped due to Limited clinical staff)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Tissue Plasminogen Activator (t-PA) Release

Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively. Change is the difference of t-PA at baseline and t-PA after bradykinin 400 ng/min (NCT00166166)
Timeframe: Baseline, 30 minutes

Intervention	ng/mL (Mean)
Healthy Controls	5.6

Change in Tissue Plasminogen Activator (t-PA) Release After Fluconazole and Bradykinin Administration

Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively. Change is the difference of t-PA after fluconazole and t-PA after bradykinin 400 ng/min (NCT00166166)
Timeframe: 30 minutes, 60 minutes

Intervention	ng/mL (Mean)
Healthy Controls	4.4

Change in Tissue Plasminogen Activator (t-PA) Release After Fluconazole, Tetraethylammonium (TEA), and Bradykinin Administration

Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively. Change is the difference of t-PA after fluconazole and tetraethylammonium (TEA) and t-PA after bradykinin 400 ng/min (NCT00166166)
Timeframe: 60 minutes, 90 minutes

Intervention	ng/mL (Mean)
Healthy Controls	1.6

Change in Tissue Plasminogen Activator (t-PA) Release After Tetraethylammonium (TEA) and Bradykinin Administration

Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively. Change is the difference of t-PA after Tetraethylammonium (TEA) and t-PA after bradykinin 400 ng/min (NCT00166166)
Timeframe: 30 minutes, 60 minutes

Intervention	ng/mL (Mean)
Healthy Controls	0.03

Forearm Blood Flow (FBF) After Sodium Nitroprusside Administration

Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph after administration of sodium nitroprusside. Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. (NCT00166166)
Timeframe: 5 minutes

Intervention	mL min^-1 * 100 mL^-1 (Mean)
Healthy Controls	10.4
Risk Factors	10.9

Percent Change in Forearm Blood Flow (FBF) After Administration of L-NG-monomethyl Arginine (L-NMMA)

Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph after administration of L-NG-monomethyl Arginine (L-NMMA). Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. Percent change is the difference in FBF from baseline and after L-NMMA administration. (NCT00166166)
Timeframe: Baseline, 5 minutes

Intervention	percent change (Mean)
Healthy Controls	-29
Risk Factors	-23

Percent Change in Forearm Blood Flow (FBF) After Administration of L-NG-monomethyl Arginine (L-NMMA) and Tetraethylammonium (TEA)

Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph after administration of L-NG-monomethyl Arginine (L-NMMA) and Tetraethylammonium (TEA). Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. Percent change is the difference in FBF from after L-NMMA administration and after TEA administration. (NCT00166166)
Timeframe: 5 minutes, 10 minutes

Intervention	percent change (Mean)
Healthy Controls	-38
Risk Factors	-39

Percent Change in Forearm Blood Flow (FBF) After Fluconazole Administration

Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph at rest and after administration of fluconazole. Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. Percent change is the difference from baseline FBF and after fluconazole administration. (NCT00166166)
Timeframe: Baseline, 5 minutes

Intervention	percent change (Mean)
Healthy Controls	-13
Risk Factors	-17

Percent Change in Forearm Blood Flow (FBF) After Fluconazole and Tetraethylammonium (TEA) Administration

Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph after administration of fluconazole and Tetraethylammonium (TEA) administration. Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. Percent change is the difference from FBF after fluconazole administration and after Tetraethylammonium (TEA) administration. (NCT00166166)
Timeframe: 5 minutes, 10 minutes

Intervention	percent change (Mean)
Healthy Controls	-22

Percent Change in Forearm Blood Flow (FBF) After L-NG-monomethyl Arginine (L-NMMA) and Fluconazole Administration

Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph after L-NMMA administration and administration of fluconazole. Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. Percent change is the difference in FBF after L-NMMA administration and then fluconazole administration. (NCT00166166)
Timeframe: 5 minutes, 10 minutes

Intervention	percent change (Mean)
Healthy Controls	-26
Risk Factors	-26

Percent Change in Forearm Blood Flow (FBF) After Tetraethylammonium (TEA) Administration

Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph at rest and after administration of tetraethylammonium (TEA). Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. Percent change is the difference from baseline FBF and after TEA administration. (NCT00166166)
Timeframe: Baseline, 5 minutes

Intervention	percent change (Mean)
Healthy Controls	-18
Risk Factors	-24

Trials

1 trial available for tetraethylammonium and Hypercholesterolemia

Article	Year
Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. Circulation, 2011, May-24, Volume: 123, Issue:20 Topics: Acetylcholine; Adult; Biological Factors; Bradykinin; Cytochrome P-450 Enzyme System; Endothelium, V	2011

Other Studies

3 other studies available for tetraethylammonium and Hypercholesterolemia

Article	Year
Effects of exercise training and hypercholesterolemia on adenosine activation of voltage-dependent K+ channels in coronary arterioles. Journal of applied physiology (Bethesda, Md. : 1985), 2008, Volume: 105, Issue:6 Topics: 4-Aminopyridine; Adenosine; Animals; Arterioles; Cholesterol, Dietary; Colforsin; Coronary Vessels;	2008
Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery. European journal of pharmacology, 2004, Aug-30, Volume: 497, Issue:3 Topics: Animals; Biological Factors; Charybdotoxin; Endothelium, Vascular; Enzyme Inhibitors; Hypercholester	2004
Effect of hypercholesterolemia on Ca(2+)-dependent K(+) channel-mediated vasodilatation in vivo. American journal of physiology. Heart and circulatory physiology, 2000, Volume: 279, Issue:4 Topics: Acetylcholine; Animals; Apamin; Bradykinin; Calcium; Charybdotoxin; Drug Combinations; Enzyme Inhibi	2000